ClariVest Asset Management’s Amicus Therapeutics FOLD Stock Holding History

ClariVest Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-48,838	Closed	-$482K	–	778
2021 Q1	$482K	Sell	48,838 -2,900	-6%	-$44.9K	0.02%	421
2020 Q4	$1.19M	Sell	51,738 -70,493	-58%	-$1.44M	0.04%	256
2020 Q3	$1.73M	Sell	122,231 -5,586	-4%	-$81.4K	0.06%	244
2020 Q2	$1.93M	Buy	127,817 +29,808	+30%	+$363K	0.05%	234
2020 Q1	$906K	Buy	+98,009	New	+$932K	0.03%	318
2015 Q4	–	Sell	-75,546	Closed	-$1.06M	–	626
2015 Q3	$1.06M	Sell	75,546 -121,260	-62%	-$1.9M	0.03%	271
2015 Q2	$2.79M	Sell	196,806 -26,004	-12%	-$313K	0.08%	166
2015 Q1	$2.42M	Sell	222,810 -2,129	-0.9%	-$18.8K	0.07%	166
2014 Q4	$1.87M	Sell	224,939 -798	-0.4%	-$5.48K	0.07%	168
2014 Q3	$1.34M	Buy	+225,737	New	+$1.18M	0.05%	212

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClariVest Asset Management's FOLD Position: Q2 2021 in Review

ClariVest Asset Management sold out of Amicus Therapeutics (FOLD) in Q2 2021, closing a stake of 48,838 shares — an estimated $482K sold.

ClariVest Asset Management first reported a position in FOLD in Q3 2014 and held it in 10 quarters. The position peaked at $2.79M in Q2 2015. 235 funds tracked by Wall St. Rank hold FOLD as of Q2 2021.

ClariVest Asset Management reported no remaining Amicus Therapeutics position as of Q2 2021 after selling out during the quarter.
ClariVest Asset Management sold 48,838 Amicus Therapeutics shares in Q2 2021, an estimated $482K.
ClariVest Asset Management first reported a position in Amicus Therapeutics in Q3 2014 and held it in 10 quarters.
ClariVest Asset Management's Amicus Therapeutics position peaked at $2.79M in Q2 2015.
235 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2021.

Based on ClariVest Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.